Increased Risk of Peripheral Arterial Disease After Hip Replacement: An 11-Year Retrospective Population-Based Cohort Study

Tzu-Yi Chou, Ta-Wei Su, Heng-Jeng Jou, Pei-Yu Yang, Hsuan-Ju Chen, Chih-Hsin Muo, and Chia-Hung Kao

Abstract: The correlation between hip replacement (Hip-Rep) and peripheral arterial disease (PAD) remains uncertain. Thus, we investigated the relationship between Hip-Rep and risk of developing PAD in a nationwide retrospective cohort study.

National Health Insurance data were used to assemble a cohort of patients who were diagnosed from 2000 to 2011. Patients with a history of PAD were excluded. A total of 5284 patients who received a Hip-Rep and 21,124 matched controls were enrolled. We used Cox proportional hazards regression model to analyze the adjusted risk of developing PAD.

The risk of developing PAD in the Hip-Rep group was 1.24-fold higher (95% CI = 1.05–1.48) than that in the control group. The adjusted risk of developing PAD increased with patient age; compared with patients aged 50 years or younger, the risk among those ages at least 80 years was 4.87-fold higher. Patients with diabetes exhibited the highest risk of developing PAD (HR = 1.58, 95% CI = 1.34–1.86). Compared with patients who had not received a Hip-Rep or reported any comorbidity, patients who received a Hip-Rep were 2.45-fold more likely to develop PAD (95% CI = 1.54–3.89); the risk increased with the number of comorbidities.

Hip-Reps might be independently linked with an increased risk of developing PAD. The impact of Hip-Reps on this risk was greater in women and patients ages 65 years and younger and within the first year of follow-up.

(Medicine 94(19):e870)

INTRODUCTION

Hip replacement (Hip-Rep), also called total hip arthroplasty, is a common and efficacious surgical procedure. The number of Hip-Reps rapidly increased over the past decade. Several studies have reported that Hip-Rep is associated with an increased risk of PAD; however, no research has investigated this association in an Asian context. Thus, we conducted a nationwide retrospective cohort study to examine the risk of developing PAD in patients who received a Hip-Rep, hypothesizing that the procedure might increase the risk of developing PAD.

METHODS

Data Source

This retrospective cohort study used data from the Longitudinal Health Insurance Database (LHID). The LHID is a...
subset of the National Health Insurance Research Database (NHIRD) program, which was established by the Taiwan Bureau of NHI (BNHI). The NHI program, inaugurated in 1995, covers approximately 99% of the more than 23 million people in Taiwan.

By the end of 2010, the BNHI had contracts with all hospitals and 92% of clinics nationwide. Each person covered by the NHI receives a unique identification number. All NHI data sets can be interlinked using these anonymized identification numbers. Comprehensive information on insured patients, including demographic data, clinic visit dates, disease diagnoses, and prescription details, is included in the LHID. The diagnostic codes used were those in the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). This study was approved by the institutional review board of China Medical University and Hospital, Taiwan (CMU-REC-101–012).

**Study Population**

This national population-based cohort study included 2 groups. We identified 5284 patients who received a Hip-Rep (ICD-9-CM codes 815.1 and 815.2) but had no history of PAD (ICD-9-CM codes 440.0, 440.2, 440.3, 440.4, 440.9, 443, 444.0, 444.22, 444.4, 447.8, and 447.9) from 2000 to 2011. The date of Hip-Rep was used as the index date. A control group was randomly selected from insured people with no Hip-Rep or history of PAD and was matched with the Hip-Rep group at a ratio of approximately 4:1 according to sex, age, and year of Hip-Rep. The index dates of the control cohort were assigned according to days and months randomly, and the index years were the same year as those of the matched cases. In total, 5284 patients were included in the Hip-Rep group and 21,124 patients comprised the control group.

**Covariates and Main Outcome**

Demographic factors included sex and age (in groups ages <50, 50–64, 65–79, and >80). Patients with HTN (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code 272), DM (ICD-9-CM code 250), ischemic stroke (IS) (ICD-9-CM codes 433–438), ischemic heart disease (IHD, ICD-9-CM codes 410–414), chronic obstructive pulmonary disease (COPD, ICD-9-CM codes 490, 491, 495, and 496), or chronic kidney disease (CKD, ICD-9-CM code 585) diagnosed before the index date were considered to have a comorbidity.

We identified a significant outcome of PAD development (ICD-9-CM codes 440.0, 440.2, 440.3, 440.4, 440.9, 443, 444.0, 444.22, 444.4, 447.8, and 447.9). Patients were followed from the index date until either December 2011, onset of PAD, death, or withdrawal from the NHI.

**Statistical Analysis**

The distribution of sex, age, and comorbidities (HTN, hyperlipidemia, DM, IS, IHD, COPD, and CKD) between the Hip-Rep and the control groups were compared. Differences were examined using the chi-square tests for categorical variables and the Student t test for continuous variables. Follow-up time in person-years was calculated for each person from the index date until PAD development. The incidence rate was calculated by dividing the number of PAD diagnoses by the number of person-years. The cumulative incidence of PAD was computed using the Kaplan–Meier method, and the difference in cumulative incidence between the groups was tested using a log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models to assess the association between Hip-Rep and PAD, with sex, age, and comorbidities adjusted for. All analyses were performed using SAS Version 9.3 (SAS Institute, Cary, NC). The significance level was set at less than 0.05 for the 2-sided P value.

**RESULTS**

A total of 5284 patients who had received a Hip-Rep between 2000 and 2011 was frequency-matched according to sex, age, and year of Hip-Rep with 21,124 patients who had not received a Hip-Rep. The Hip-Rep group had a mean age of 67.2 years (standard deviation [SD] = 16.2 years) and a slight female predominance (52.5%). Compared with the control group, the Hip-Rep group exhibited a significantly higher prevalence of HTN (58.5% vs 51.1%), DM (22.1% vs 17.4%), IS (27.7% vs 19.9%), IHD (30.0% vs 26.9%), COPD (32.6% vs 28.1%), and CKD (5.2% vs 2.6%) (Table 1).

The results of Kaplan–Meier analysis revealed that the Hip-Rep group had a higher cumulative incidence rate of PAD than did the control group (log-rank test, P = 0.001) (Figure 1). During the follow-up period, the incidence rates of PAD for the Hip-Rep and control groups were 7.79 and 5.79 per 1000 person-years, respectively. After adjustments for sex, age, and comorbidities, patients who received a Hip-Rep exhibited an increased risk of PAD compared with those in the control group (adjusted HR = 1.24, 95% CI = 1.05–1.48) (Table 2). Compared with patients ages 50 years and younger, the adjusted HR of PAD was 3.46-fold higher among those ages 50–64 years, 4.61-fold higher among those ages 65–79 years, and 4.87-fold higher among those ages 80 years and older. Multivariate Cox proportional hazards analysis revealed that PAD was independently associated with HTN (adjusted HR = 1.35, 95% CI = 1.25–1.63), DM (adjusted HR = 1.58, 95% CI = 1.34–1.86), IHD (adjusted HR = 1.70, 95% CI = 1.44–1.99), and CKD (adjusted HR = 1.75, 95% CI = 1.29–2.37).

**TABLE 1. Demographics Between Hip-Rep and Comparison Group**

|          | Hip-Rep (N = 5284) | Comparison (N = 21,124) | P-Value |
|----------|-------------------|-------------------------|---------|
| Men      | 2508              | 10,027                  | 0.97    |
| Age, year|                   |                         | 0.99    |
| <50      | 942               | 3768                    | 17.8    |
| 50–64    | 1053              | 4212                    | 19.9    |
| 65–79    | 2045              | 8180                    | 38.7    |
| >80      | 1244              | 4964                    | 23.5    |
| Mean (SD)| 67.2 (16.2)       | 66.5 (16.1)             |         |

| Comorbidity | Hip-Rep | Comparison | P-Value |
|-------------|---------|------------|---------|
| HTN         | 3093    | 10,801     | <0.0001 |
| Hyperlipidemia | 1478    | 5646       | 0.07    |
| DM          | 1165    | 3685       | <0.0001 |
| IHD         | 1466    | 4209       | 0.0001  |
| COPD        | 1585    | 5687       | <0.0001 |
| CKD         | 1724    | 5936       | <0.0001 |
| PKD         | 276     | 558        | 2.64    |

CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, DM = diabetes mellitus, Hip-Rep = hip replacement, HTN = hypertension, IHD = ischemic heart disease, IS = ischemic stroke, SD = standard deviation. Chi-square test and t test.
Stratified by sex, the incidence rates of PAD in women and men who received a Hip-Rep were 9.34 and 9.17 per 1000 person-years, respectively, both higher than those in women and men in the control cohort (6.54 and 5.01 per 1000 person-years, respectively). In addition, women who received a Hip-Rep exhibited a 1.29-fold (95% CI = 1.03–1.61) higher risk of developing PAD than did women who did not receive a Hip-Rep. Among the age groups, a significantly higher HR of PAD was observed among patients who received a Hip-Rep while ages 65 years or younger (adjusted HR = 1.69, 95% CI = 1.03–2.78 and adjusted HR = 1.63, 95% CI = 1.01–2.63, respectively) (Table 3).

Compared with patients without the examined diseases and Hip-Rep treatment, patients received Hip-Rep without any comorbidity had a 2.45-fold risk for PAD (95% CI = 1.54–3.89). Patients with only DM exhibited the highest risk of developing PAD (adjusted HR = 3.66, 95% CI = 1.67–7.99), followed by those with only IS (adjusted HR = 3.44, 95% CI = 1.71–6.94) compared to people with no comorbidity.

### TABLE 2. Hazard Ratio and 95% Confidence Intervals for PAD and PAD-Associated Risk Factor

| Hip-Rep | Crude (95% CI) | Adjusted (95% CI) |
|---------|----------------|------------------|
| Replacement | |
| No | 586 | 5.79 | 1.00 |
| Yes | 173 | 7.79 | 1.34 (1.13–1.59)*** |
| Gender | |
| Women | 443 | 7.05 | 1.35 (1.16–1.55)*** |
| Men | 316 | 5.22 | 1.00 |
| Age, year | |
| <50 | 30 | 1.11 | 1.00 |
| 50–64 | 129 | 4.90 | 4.40 (2.96–6.55)*** |
| 65–79 | 410 | 8.27 | 7.42 (5.12–10.6)*** |
| >80 | 190 | 9.25 | 8.28 (5.63–12.2)*** |
| Comorbidity | |
| HTN | No | 213 | 3.31 | 1.00 |
| Yes | 546 | 9.54 | 2.78 (2.37–3.26)*** |
| DM | No | 532 | 5.10 | 1.00 |
| Yes | 227 | 11.94 | 2.33 (1.99–2.72)*** |
| IS | No | 511 | 5.05 | 1.00 |
| Yes | 248 | 11.14 | 2.19 (1.88–2.55)*** |
| IHD | No | 393 | 4.23 | 1.00 |
| Yes | 366 | 12.02 | 2.83 (2.46–3.27)*** |
| COPD | No | 494 | 5.35 | 1.00 |
| Yes | 265 | 8.53 | 1.58 (1.36–1.84)*** |
| CKD | No | 713 | 5.91 | 1.00 |
| Yes | 46 | 16.91 | 2.83 (2.10–3.81)*** |

CI = confidence interval, CKD = chronic kidney disease. IR, incidence density rate, per thousand person-years, COPD = chronic obstructive pulmonary disease, DM = diabetes mellitus, Hip-Rep = hip replacement, HR = hazard ratio, HTN = hypertension, IHD = ischemic heart disease, IS = ischemic stroke, SD = standard deviation. Manually adjusted for sex, age and comorbidity. *P < 0.05, **P < 0.01, ***P < 0.001

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
no comorbidity. Among patients who received a Hip-Rep, those with four or more comorbidities exhibited a significantly increased risk of PAD (adjusted HR = 6.00, 95% CI = 4.16–8.67), followed by those with any three comorbidities (adjusted HR = 4.32, 95% CI = 2.84–6.59), those with any two comorbidities (adjusted HR = 3.49, 95% CI = 2.25–5.43), and those with one comorbidity (adjusted HR = 2.80, 95% CI = 1.74–4.49) (Table 4).

DISCUSSION

We conducted this nationwide population-based retrospective cohort study to elucidate the relationship between Hip-Rep and the risk of developing PAD. After adjustments for sex, age, HTN, DM, IS, IHD, COPD, and CKD, patients who received a Hip-Rep exhibited a 1.24-fold higher risk of developing PAD than did patients in the control group. Age, HTN, DM, IHD, COPD, and CKD were also significantly associated with PAD. Most notably, a significantly higher risk of developing PAD was noted among women who received a Hip-Rep, patients who received a Hip-Rep while ages 65 years or younger, and patients who received a Hip-Rep within the first follow-up year.

Our data revealed that advanced age, rather than sex, influenced the risk of developing PAD. This outcome was consistent with those in previous studies. However, this study did not demonstrate that patients with only hyperlipidemia were at increased risk of developing PAD (compared with patients without the examined diseases), as previous studies have shown. Using more cases or longer study periods might TABLE 3. Hazard Ratio and 95% Confidence Intervals for PAD Compared to Comparison Cohort Stratified by Gender, Age, and Follow-up Year

| Gender | Case No. | IR | HR (95% CI) |
|--------|----------|----|-------------|
| Women  | 106      | 9.34 | 1.29 (1.03–1.61)* |
| Men    | 67       | 9.17 | 1.19 (0.91–1.56) |
| Age, year |        |    |             |
| <65    | 48       | 4.77 | 1.67 (1.18–2.36)** |
| 65–79  | 86       | 9.97 | 1.13 (0.89–1.44) |
| >80    | 39       | 11.05 | 1.18 (0.83–1.68) |
| Follow-up year | | | |
| <0.5  | 23       | 9.29 | 1.69 (1.03–2.78)* |
| 0.5–1.0 | 25      | 11.22 | 1.63 (1.01–2.63)* |
| >1.0  | 125      | 7.14 | 1.13 (0.93–1.38) |

CI = confidence interval, Hip-Rep = hip replacement, HR = hazard ratio, IR = incidence density rate, per thousand person-years, PAD = peripheral arterial disease. *P < 0.05, **P < 0.01.
†Manually adjusted for sex, age, and comorbidity.
‡Adjusted for sex, age, and comorbidity.

TABLE 4. Joint Effect for PAD between Hip Replacement and PAD-Associated Risk Factor

| Variable | N | Case No. | IR | HR (95% CI) |
|----------|---|----------|----|-------------|
| None     | 6895 | 63      | 1.65 | 1.00 |
| Only Hip-Rep | 1314 | 25      | 3.83 | 2.45 (1.54–3.89)** |
| Only HTN | 1753 | 45      | 5.07 | 2.25 (1.52–3.32)** |
| Only Hyperlipidemia | 520 | 8       | 2.99 | 1.66 (0.80–3.47) |
| Only DM  | 227  | 7       | 6.73 | 3.66 (1.67–7.99)** |
| Only IS  | 232  | 9       | 8.53 | 3.64 (1.80–7.35)** |
| Only IHD | 226  | 9       | 7.53 | 3.44 (1.71–6.94)** |
| Only COPD | 982 | 16      | 3.5  | 1.76 (1.01–3.05)* |
| Only CKD | 23   | 0       | 0.00 | – |
| Without Hip-Rep and with any two or more comorbidities | 10,266 | 429 | 9.84 | 4.10 (3.10–5.42)** |
| Hip-Rep with any one comorbidity | 976 | 24      | 5.54 | 2.80 (1.74–4.49)** |
| Hip-Rep with any two comorbidities | 949 | 30      | 7.75 | 3.49 (2.25–5.43)** |
| Hip-Rep with any three comorbidities | 902 | 35      | 10.14 | 4.32 (2.84–6.59)** |
| Hip-Rep with any four or more comorbidities | 1143 | 59      | 14.65 | 6.00 (4.16–8.67)** |

CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, DM = diabetes mellitus, Hip-rep = hip replacement, HTN = hypertension, IHD = ischemic heart disease, IS = ischemic stroke, SD = standard deviation. Adjusted for age and sex. *P < 0.05, **P < 0.01, ***P < 0.001.
reveal the positive association between hyperlipidemia and the risk of developing PAD.

This study revealed that patients who received a Hip-Rep had more comorbidities (HTN, DM, and CKD) than did patients in the control group. Moreover, HTN, DM, and CKD are associated with PAD.\(^6,16,17\) Accordingly, one possible reason for the increased risk of PAD in the Hip-Rep group is that the patients in the group had a significantly higher prevalence of comorbidities. We did not have sufficient data on the prevalence of comorbidities in Asian patients who received a Hip-Rep. However, a 1990–2004 National Hospital Discharge Survey-based statistical analysis in the United States reported that patients who received a Hip-Rep had an increased likelihood of developing DM, HTN, hypercholesterolemia, obesity, pulmonary disease, or CAD.\(^2,8\)

Alternatively, the population of patients with PAD identified in this study might have been underestimated because PAD is frequently underdiagnosed.\(^10,19\) Thus, the number of patients with PAD was likely greater than that diagnosed and enrolled; therefore, the impact of Hip-Rep on the risk of developing PAD might have been underestimated.

Limitations were also caused by incomplete data. First, the diagnoses recorded in the National Health Insurance Research Database (NHIRD) are primarily for administrative billing purposes and were not validated for academic purposes. Second, data on symptoms of PAD, family medical history, lifestyle, smoking habit, BMI status, laboratory data, and imaging findings, which are all potentially relevant to this study, are not included in the NHIRD. Third, the evidence derived from a retrospective cohort study is generally of lower methodological quality than that of prospectively randomized trials because a retrospective cohort study design is subject to numerous biases related to adjustments for confounding factors. Despite our meticulous study design with the adequate control of confounding factors, a key limitation was that bias could have existed because of possible unmeasured or unknown confounders. Thus, a bias such as PAD patients with a mistaken diagnosis of arthrosis might occur. Fourth, causality could not be established beyond doubt in this observational study.

We could not verify the exact temporal relationship between Hip-Rep and PAD by using the NHIRD data.

Our findings have clinical importance. First, the results indicated that Hip-Rep independently increases the risk of developing PAD. Because Hip-Rep has been reported as being associated with an increased risk of atherosclerosis and unspecified cardiovascular disease\(^2\) and arterial thrombosis,\(^3\) few studies have examined the specific relationship between Hip-Rep and PAD or considered Hip-Rep an independent risk factor for developing PAD. Some reports suggested a positive association between Hip-Rep and risk of developing PAD. For example, Islam and Blake reported a total infrarenal aortic occlusion condition after primary Hip-Rep, and that an aortobifemoral bypass resolved the problem.\(^20\) Hemodynamic change, or vascular compromise, was proposed as a potential factor or an aggravated factor for developing PAD.\(^15,21\) However, future prospective, large-scale research; or meta-analyses might validate this finding. The second clinically notable aspect of this study is that the more comorbidities in the Hip-Rep group, the more risk of PAD and related morbidity and mortality; physicians should consider these conditions and treat patients accordingly.

This study has several strengths. First, this study is the first to examine the relationship between Hip-Rep and the risk of developing PAD in an Asian country. Second, we conducted this retrospective cohort research using nationwide population data from the NHIRD, which covers a highly representative sample of the general population of Taiwan because the reimbursement policy is universal and operated only by the government. Moreover, all insurance claims are scrutinized by peer review and medical reimbursement specialists. PAD was accurately diagnosed and coded (ICD-9 codes) by the specialists according to the standard diagnosed criteria including typical symptoms/signs, laboratory data, and imaging findings. In addition, if the doctors or hospitals make the wrong codes or diagnoses, the National Health Insurance Administration will punish them with a lot of penalty. Therefore, the diagnoses of PAD in this study were highly reliable. Third, the joint effect of Hip-Rep and different numbers of comorbidities are discussed, possibly elucidating the risk of PAD among patients with multiple comorbidities.

In conclusion, patients who received a Hip-Rep might have an increased risk of developing PAD. Age, HTN, DM, IHD, and CKD are also crucial risk factors for developing PAD. Patients who receive a Hip-Rep and have the aforementioned comorbidities are at an even higher risk of developing PAD. An increased risk of developing PAD was present among women who received a Hip-Rep, patients who received a Hip-Rep while ages 65 years or younger, and patients who received a Hip-Rep within the first follow-up year in our study period. Although Hip-Rep is an orthopedic procedure, it might influence the vascular system profoundly. We suggest that further research involving larger samples and a more rigorous methodology be conducted.

ACKNOWLEDGMENTS

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212–113002); China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092); NRPB Stroke Clinical Trial Consortium (MOST 103–2325-B-039–006); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and Health, and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212–124–002, Taiwan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

REFERENCES

1. Chechak O, Khashan M, Lador R, et al. Surgical approach and prosthesis fixation in hip arthroplasty world wide. Arch Orthop Trauma Surg. 2013;133:1595–1600.
2. Lovold ST, Ong KL, Lau EC, et al. Mortality, cost, and downstream disease of total hip arthroplasty patients in the medicare population. J Arthroplasty. 2014;29:242–246.
3. Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med. 2009;361:787–794.
4. Kurtz S, Mowat F, Ong K, et al. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am. 2005;87:1487–1497.
5. Lai YS, Wei HW, Cheng CK. Incidence of hip replacement among national health insurance enrollees in Taiwan. J Orthop Surg Res. 2008;3:42.
6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621.

7. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538–545.

8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.

9. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–S67.

10. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc. 2010;85:678–692.

11. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49–57.

12. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.

13. Lussana F, Squizzato A, Perumnian ET, et al. A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty. Thromb Res. 2014;134:599–603.

14. Trousdale RT, Donnelly RS, Hallett JW. Thrombosis of an aortobifemoral bypass graft after total hip arthroplasty. J Arthroplasty. 1999;14:386–390.

15. Leung AG, Cabanela ME. Aortic thrombosis after acetabular revision of a total hip arthroplasty. J Arthroplasty. 1998;13:961–965 Review.

16. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169.

17. Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis. 2014;21:460–471.

18. Liu SS, Della Valle AG, Besculides MC, et al. Trends in mortality, complications, and demographics for primary hip arthroplasty in the United States. Int Orthop. 2009;33:643–651.

19. Marrett E, DiBonaventura Md, Zhang Q. Burden of peripheral arterial disease in Europe and the United States: a patient survey. Health Qual Life Outcomes. 2013;11:175.

20. Islam KA, Blake SM. An unusual cause for a painful Birmingham hip resurfacing. Ann R Coll Surg Engl. 2013;95:e10–e11.

21. Smith JW, Pellicci PM, Sharrock N, et al. Complications after total hip replacement. The contralateral limb. J Bone Joint Surg Am. 1989;71:528–535.